These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Increased serum soluble Fas in patients with Graves' disease. Hiromatsu Y; Bednarczuk T; Soyejima E; Miyake I; Yang D; Fukazawa H; Nonaka K Thyroid; 1999 Apr; 9(4):341-5. PubMed ID: 10319938 [TBL] [Abstract][Full Text] [Related]
5. Soluble Fas in serum from patients with renal cell carcinoma. Nonomura N; Nishimura K; Ono Y; Fukui T; Harada Y; Takaha N; Takahara S; Okuyama A Urology; 2000 Jan; 55(1):151-5. PubMed ID: 10654915 [TBL] [Abstract][Full Text] [Related]
6. Plasma soluble fas and soluble fas ligand in chronic glomerulonephritis. Sano H; Asano K; Minatoguchi S; Hiraoka J; Fujisawa K; Nishigaki K; Yasuda N; Kumada H; Takemura M; Ohashi H; Seishima M; Fujiwara T; Fujiwara H Nephron; 1998 Oct; 80(2):153-61. PubMed ID: 9736812 [TBL] [Abstract][Full Text] [Related]
7. Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism. Nabipour I; Kalantarhormozi M; Assadi M; Jafari SM; Gharibi M; Ahmadi E; Sanjdideh Z Endocrine; 2010 Dec; 38(3):406-11. PubMed ID: 21042884 [TBL] [Abstract][Full Text] [Related]
8. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma. Mouawad R; Khayat D; Soubrane C Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407 [TBL] [Abstract][Full Text] [Related]
9. Increased serum levels of soluble Fas in progressive B-CLL. Osorio LM; Aguilar-Santelises M; De Santiago A; Hachiya T; Mellstedt H; Jondal M Eur J Haematol; 2001 May; 66(5):342-6. PubMed ID: 11422415 [TBL] [Abstract][Full Text] [Related]
10. Circulating nuclear matrix protein in Graves' disease. Hara H; Morita Y; Sato R; Ban Y Endocr J; 2002 Jun; 49(3):343-7. PubMed ID: 12201219 [TBL] [Abstract][Full Text] [Related]
11. Single, very low dose (0.03 mg) of recombinant human thyrotropin (rhTSH) effectively increases radioiodine uptake in the I-131 treatment of large nontoxic multinodular goiter. Mojsak MN; Abdelrazek S; Szumowski P; Rogowski F; Sykała M; Kostecki J; Kociura-Sawicka A; Jurgilewicz D; Myśliwiec J Nucl Med Rev Cent East Eur; 2016; 19(1):3-11. PubMed ID: 26841373 [TBL] [Abstract][Full Text] [Related]
12. Elevated soluble Fas/APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumours. Tomokuni A; Aikoh T; Matsuki T; Isozaki Y; Otsuki T; Kita S; Ueki H; Kusaka M; Kishimoto T; Ueki A Clin Exp Immunol; 1997 Nov; 110(2):303-9. PubMed ID: 9367417 [TBL] [Abstract][Full Text] [Related]
13. An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. Yasuda N; Gotoh K; Minatoguchi S; Asano K; Nishigaki K; Nomura M; Ohno A; Watanabe M; Sano H; Kumada H; Sawa T; Fujiwara H Respir Med; 1998 Aug; 92(8):993-9. PubMed ID: 9893764 [TBL] [Abstract][Full Text] [Related]
14. Increased serum thyroglobulin concentrations and impaired thyrotropin response to thyrotropin-releasing hormone in euthyroid subjects with endemic goiter in Sicily: their relation to goiter size and nodularity. Vermiglio F; Benvenga S; Melluso R; Catalfamo S; Princi P; Battiato S; Consolo F; Trimarchi F J Endocrinol Invest; 1986 Oct; 9(5):389-96. PubMed ID: 3098822 [TBL] [Abstract][Full Text] [Related]